A case of myelodysplastic syndrome with t(10;18)(q26;q21)

Yusuke Ohba¹, Minami Yamada-Fujiwara²,³, Tadanori Minagawa⁴, Suguru Watanabe⁴, Yoko Okitsu⁵,⁶, Yoshihiko Izumi¹, Junichi Kameoka², Shinichiro Takahashi¹,⁶

Abstract:
An 82-year-old male was admitted. Pancytopenia, a slightly low white blood cell count (3400/µL), and low levels of red blood cells (2.65 × 10⁶/µL), hemoglobin (10.4 g/dL), and platelets (118,000/µL) were observed. Bone marrow aspiration was performed, revealing hypocellular bone marrow and normal blast levels (0.6%) with no dysplasia. G-band chromosome analysis revealed the karyotype 45,X,−Y [3]/45, idem, t(10;18)(q26;q21)[13]/46,XY[4]. The patient was diagnosed with myelodysplastic syndrome, unclassified (MDS–U). This is the first case report demonstrating a patient with the chromosomal translocation, t(14;18)(q32;q21), which is extremely rare. This chromosomal aberration was critical for the diagnosis of MDS in this patient.

Keywords:
Chromosome banding, myelodysplastic syndromes, t(10;18)(q26;q21)

Introduction

In the WHO 2008 criteria revised in 2016, for a patient with clinical and other laboratory features, a presumptive diagnosis of myelodysplastic syndrome (MDS) can be made if a specific clonal chromosomal abnormality is present. The balanced abnormalities included in the 2008 criteria were t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21.1), t(2;11)(p21;q23), inv (3)(q21q26.2), and t(6;9)(p23;q34),[1] while those further included in the 2016 criteria were t(5;12)(q32;p13.2), t(5;7)(q32;q11.2), t(5;17)(q32;p13.2), t(5;10)(q32;p21.2), and t(3;5)(q25.3;q35.1).[2] Recently, we encountered a patient with pancytopenia and what appears to be an extremely rare chromosomal abnormality, t(10;18)(q26;q21). As there was no obvious dysplasia or increase in blasts, we considered this reciprocal translocation as a “balanced abnormality” and diagnosed the patient with MDS, unclassified (MDS–U) according to the WHO classification system.

Case Report

An 82-year-old male suffering from severe chest pain was taken by ambulance to a clinic. The day after, he received coronary angiography, and stenosis was observed in the right coronary artery. His chest pain persisted after angiography. Unstable angina was suspected, and the patient was transferred to the Cardiovascular Medicine Department at the Tohoku Medical and Pharmaceutical University Hospital to receive a percutaneous coronary intervention.

Upon admission to our hospital, the patient’s white blood cell count was slightly low (3,400/µL), and low red blood cell (2.65 × 10⁶/µL), hemoglobin (9.3 g/dL), and platelet (118,000/µL) levels were also observed [Table 1]. Echocardiography revealed severe aortic valve stenosis. Aortic valvuloplasty and coronary artery bypass graft surgery were performed.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Department of Clinical Laboratory, 2Hematology and Rheumatology, 4Cardiovascular Surgery and 6Blood Transfusion, Tohoku Medical and Pharmaceutical University Hospital, 3Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 2Division of Blood Transfusion and Cell Therapy, Tohoku University Hospital, Sendai, Japan

Address for correspondence:
Prof. Shinichiro Takahashi,
Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1, Fukuura, Miyaginokku, Sendai 983-8536, Japan.
E-mail: shintakahashi@tohoku-mpu.ac.jp

Submission: 08-04-2019
Accepted: 22-11-2019

Published online: 2020-04-07
Table 1: Laboratory findings at first visit and the result of bone marrow examination

| Complete blood count |  |
|----------------------|--|
| WBC                  | 3.4x10^3/µL |
| Seg                  | 58.7%      |
| Eosino               | 3.6%       |
| Baso                 | 0.6%       |
| Lymph                | 25.8%      |
| Mono                 | 11.3%      |
| RBC                  | 2.65x10^3/µL |
| Hb                   | 9.3g/dL    |
| Ht                   | 28%        |
| MCV                  | 105.4L     |
| PLT                  | 18x10^3/µL |
| PT                   | 14.4 sec   |
| APTT                 | 28.5 sec   |
| D-dimer              | 2.91 µg/mL |

**Biochemistry test**

|                        |            |
|------------------------|------------|
| T-Bil                  | 0.7 mg/dL  |
| AST                    | 33 U/L     |
| ALT                    | 28 U/L     |
| LD                     | 167 U/L    |
| ALP                    | 209 U/L    |
| g-GTP                  | 63 U/L     |
| CK                     | 41 U/L     |
| CK-MB                  | <10 U/L    |
| Troponin T             | 0.017 ng/mL|
| BUN                    | 15mg/dL    |
| CRE                    | 1.2mg/dL   |
| UA                     | 5.3mg/dL   |
| TP                     | 6.2mg/dL   |
| Alb                    | 3.7mg/dL   |
| T-CHO                  | 154mg/dL   |
| HDL-C                  | 56mg/dL    |
| LDL-C                  | 85mg/dL    |
| Na                     | 141mEq/L   |
| K                      | 4.1mEq/L   |
| Cl                     | 111mEq/L   |
| Ca                     | 8.7mg/dL   |
| IP                     | 3.1mg/dL   |
| Fe                     | 92µg/dL    |
| UIBC                   | 131µg/dL   |
| TIBC                   | 223µg/dL   |
| Ferritin               | 155ng/mL   |
| Zn                     | 62µg/dL    |
| CRP                    | 0.05mg/dL  |
| BNP                    | 58.6pg/mL  |
| FBS                    | 121mg/dL   |
| HbA1c                  | 5.5%       |

**Bone marrow examination**

| Cellularity          | hypocellular marrow |
|----------------------|----------------------|
| M/E                  | 2.6                  |
| Blast                | 0.6%                 |
| Promyelo             | 2.2%                 |
| Myelo                | 9.4%                 |
| Meta                 | 11.4%                |
| Stab                 | 14.4%                |

During the surgery, bone marrow aspiration from the sternum was performed. The aspiration was examined morphologically and cytogenetically. The patient’s bone marrow was observed to be hypocellular with no obvious dysplasia [Figure 1a and b]. The blast percentage was within the normal range at 0.6% [Figure 1A and B, and Table 1]. G-banding analysis of the bone marrow sample revealed that the patient had a chromosomal translocation: among the 20 cells analyzed,
three cells were karyotype A (45,X−Y), 13 cells were karyotype B (45, idem, t(10;18)(q26;q21)), and four cells were karyotype C (46, XY) [Figure 1C]. The patient was diagnosed with MDS–U. The patient remains carefully observed in our hospital as an outpatient thereafter.

**Discussion**

We recently reported the usefulness of careful histogram analysis of automatic blood cell analyzer results for acute leukemia, which assists with rapid morphological findings for blasts and abnormal cells.[3] However, not only morphologic but also cytogenetic studies are necessary to diagnose hematologic malignancies; this is common knowledge for clinical hematologists. A unique feature of the present case may be that the bone marrow aspiration and chromosome analysis were ordered and performed by cardiovascular surgeons rather than hematologists during the aortic valvuloplasty and coronary artery bypass graft surgery.

We speculate that the most likely gene playing a role in the pathogenesis of this patient’s disease is BCL2. The BCL2 gene lies within 18q21.3 and is frequently translocated to the immunoglobulin heavy chain (IgH) gene enhancer region as a result of t(14;18)(q32;q21.3), which results in the over-expression of the BCL2 gene.[4] BCL2 overexpression is involved in the pathogenesis of follicular lymphoma by preventing apoptosis of the germinal center B-cells.[4] The t(14;18)(q32;q21.3) translocation can be detected by fluorescence in situ hybridization in 85% of all cases and is considered a molecular hallmark of this disease.

Not only follicular lymphoma but also several other hematopoietic malignancies are reported to be related to the aberrant expression of the BCL2 protein.[5] In particular, in MDS patients, BCL2 expression is high, while in aplastic anemia patients, BCL2 expression is low.[6] Previously, it was reported that progression to high-risk MDS correlates with elevated expression of BCL2 protein.[6] Collectively, BCL2 expression and regulation may affect the pathophysiology of MDS.

Chromosome 10 and 18 translocations are very rare. To the best of our knowledge, only four studies have reported such translocations.[7–10] In particular, the breakpoint we observed, t(10;18)(q26;q21), was unique because it is not among these reported translocations. Although we could not identify what was fused with the gene residing in 18q21.3 (possibly the BCL2 gene), since this patient is too stable to perform further analysis, these results indicate that characterizing the gene(s) affected by this rare translocation may lead to further understanding of the biology of MDS.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Vardiman JW, Thiele J, Arber DA, Bruning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-51.
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405.
3. Saito R, Yokoyama H, Meguro K, Ohba Y, Izumi Y, Takahashi S. Rapid diagnosis of mixed phenotype acute leukemia after identifying a blood histogram abnormality. Pract Lab Med 2018;12:e00101.
4. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987;317:1185-9.
5. Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3. Neoplasma 2013;60:666-75.
6. Invernizzi R, Pecci A, Bellotti L, Ascari E. Expression of p53, Bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma 2001;42:481-9.
7. Tuck-Muller CM, Dyken PR, Li S, Chen H, Labbè E, Wertelecki W. Translocation 10;18 in a patient with juvenile neuronal ceroid-lipofuscinosis (Batten disease). Am J Med Genet 1995;57:168-71.
8. Gomi K, Hamanoue S, Tanaka M, Matsumoto M, Kitagawa N, Niwa T, et al. Anaplastic sarcoma of the kidney with chromosomal abnormality: First report on cytogenetic findings. Hum Pathol 2010;41:1495-9.
9. Rethoré MO, Prieur M, de Blois MC, Naffah J, Ravel A, Villain E, et al. Reciprocal syndromes caused by deficiency duplication resulting from maternal t(10;18)(p12;q22) translocation. Ann Genet 1985;28:149-53.
10. Forabosco A, Bernasconi S, Giovannelli G, Dutrillaux B. Trisomy of the distal third of the long arm of chromosome 10. Report of a new case due to a familial translocation t(10;18) (q24;p11). Helv Paediatr Acta 1975;30:289-95.